TRIM33 and cancer: Interestingly, there are other anti–TIF1-γ–positive/anti-CCAR1–negative DM patients who behave similarly to anti-CCAR1–positive patients (that is, no cancer, or delayed cancer emergence); the size of this population is at least equal to the anti-CCAR1–positive group (Figure 2D).